Archives of Gynecology and Obstetrics

, Volume 300, Issue 5, pp 1271–1277 | Cite as

Gabapentin for the management of chronic pelvic pain in women

  • M. A. AbdelHafeez
  • A. RedaEmail author
  • A. Elnaggar
  • H. EL-Zeneiny
  • J. M. Mokhles
General Gynecology



Chronic pelvic pain (CPP) is a frequent presenting symptom in gynaecology outpatient clinics. Neuromodulator pharmacological agents could be an option for treatment based on its efficacy in treating chronic pain in other conditions.


This study aimed at evaluating the efficacy of oral Gabapentin to alleviate pain in women with CPP.


In a randomized double-blinded placebo-controlled trial, 60 women suffering from chronic pelvic pain were randomly divided into two equal arms. The study group received Gabapentin 300 mg three times daily initially (900 mg), with 300 mg weekly incremental dose till pain was controlled, severe side effects occurred or maximum daily dose of 2700 mg was reached. The Primary outcome was the pain score improvement of CPP, defined as a 30% reduction in the pain score assessed by the 10-cm Visual Analogue Scale compared to baseline score.


In Gabapentin group, pain was significantly reduced at 12 and 24 weeks (mean = 5.12 ± 0.67 and 3.72 ± 0.69, respectively) than in placebo group (mean = 5.9 ± 0.92 and 5.5 ± 1.13, respectively); this difference was significant. At 24 weeks, there was significantly higher proportion of patients reporting 30% or more reduction in pain scores; 19 out of 20 patients (95%) in Gabapentin group compared to 8 out of 14 patients (57.1%) in placebo group. The relative risk for pain after gabapentin treatment was 0.5 with 95% confidence interval = 0.34 to 0.75 and number needed to treat = 3 (p = 0.007). Regarding adverse effects there was significantly higher incidence of dizziness with Gabapentin (26.1%) compared to placebo (3.3%).


Chronic pelvic pain in women may be treated sufficiently with Gabapentin.

Trial registration

The trial was registered in registry with clinical trial registration number: NCT02918760.


Chronic pelvic pain Gabapentin Visual analogue scale Chronic pain VAS 


Author contributions

AMA: study conception, developed project, interpreted data, critically revised manuscript. RA: protocol development, data interpretation, manuscript writing. EA: data analysis, manuscript writing. E-ZH: project development, revised manuscript. MJM: data collection, manuscript drafting.


No funding.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration of the Principles of Ethical Medical Research [last updated in Brazil 2013].

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Royal College of Obstetricians and Gynecologists (2019) Chronic Pelvic pain, initial management. Green-top Guideline No. 41. London: RCOG; 2012. Updated 2017. Accessed January 3, 2019; Available from:
  2. 2.
    ACOG Committee on Practice Bulletins-Gynecology (2004) ACOG Practice Bulletin No. 51 Chronic pelvic pain. Obstet Gynecol 103(3):589–605CrossRefGoogle Scholar
  3. 3.
    McDonald JS (2001) Diagnosis and treatment issues of chronic pelvic pain. World J Urol 19:200–207CrossRefGoogle Scholar
  4. 4.
    Tomaskovic I, Ruzic B, Trnski D, Kraus O (2009) Chronic prostatitis/chronic pelvic pain syndrome in males may be an autoimmune disease, potentially responsive to corticosteroid therapy. Med Hypotheses 72(3):261–262CrossRefGoogle Scholar
  5. 5.
    Woodworth D, Mayer E, Leu K et al (2015) Unique microstructural changes in the brain associated with urological chronic pelvic pain syndrome (UCPPS) revealed by diffusion tensor MRI, super-Resolution track density imaging, and statistical parameter mapping: a MAPP network neuroimaging study. PLoS One 10(10):e0140250CrossRefGoogle Scholar
  6. 6.
    Sator-Katzenschlager SM, Scharbert G, Kress KG et al (2005) Chronic pelvic pain treated with Gabapentin and amitriptyline: a randomized controlled pilot study. Wien Klin Wochenschr 117(21–22):761–768CrossRefGoogle Scholar
  7. 7.
    Walker EA, Roy-Byrne PP, Katon WJ, Jemelka R (1991) An open trial of nortriptyline in women with chronic pelvic pain. Int J Psychiatry Med 21(3):245–252CrossRefGoogle Scholar
  8. 8.
    Agarwal MM, Elsi Sy M (2017) Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin? Neurourol Urodyn 36:2028–2033CrossRefGoogle Scholar
  9. 9.
    Lewis SC, Bhattacharya S, Wu O et al (2016) Gabapentin for the management of chronic pelvic pain in women (GaPP1): a pilot randomised controlled trial. PLoS One 11(4):e0153037CrossRefGoogle Scholar
  10. 10.
    Engeler D, Baranowski AP, Borovicka J, et al; European Association of Urology (2015) Guidelines on chronic pelvic pain. Available from Accessed 3 Jan 2019
  11. 11.
    National Institute of Clinical Excellence (NICE) (2017) Neuropathic pain—pharmacological management. NICE clinical guideline 173. Issued: November 2013, Updated: February 2017. Available from: Accessed 3 Jan 2019
  12. 12.
    Sills GJ (2006) The mechanisms of action of Gabapentin and pregabalin. Curr Opin Pharmacol 6(1):108–113CrossRefGoogle Scholar
  13. 13.
    Abdi S, Lee DH, Chung JM (1998) The anti-allodynic effects of amitryptyline, Gabapentin and lidocaine in a rat model of neuropathic pain. Anesth Analg 87(6):1360–1366PubMedGoogle Scholar
  14. 14.
    Pan HL, Eisenach JC, Chen SR (1999) Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther 288(3):1026–1030PubMedGoogle Scholar
  15. 15.
    Breivik H, Borchgrevink PC, Allen SM et al (2008) Assessment of pain. Br J Anaesth 101(1):17–24CrossRefGoogle Scholar
  16. 16.
    Dworkin RH, Turk DC, Wyrwich KW et al (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9:105–121CrossRefGoogle Scholar
  17. 17.
    Malnar G (2004) Neural mechanisms of pain. Int J Fertil Womens Med 49(4):155–158PubMedGoogle Scholar
  18. 18.
    Pontati MA, Ruggieri MR (2004) Mechanisms in prostatitis/chonic pelvic pain syndrome. J Urol 172(3):839–845CrossRefGoogle Scholar
  19. 19.
    Rose MA, Kam PC (2002) Gabapentin: pharmacology and its use in pain management. Anaesthesia 57(5):451–462CrossRefGoogle Scholar
  20. 20.
    Malec-Milewska M, Horosz B, Sękowska A et al (2015) Pharmacological treatment and regional anesthesia techniques for pain management after completion of both conservative and surgical treatment of endometriosis and pelvic adhesions in women with chronic pelvic pain as a mandated treatment strategy. Ann Agric Environ Med 22(2):353–356CrossRefGoogle Scholar
  21. 21.
    Wiffen PJ, Derry S, Bell RF, et al (2017) Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 6: CD007938Google Scholar
  22. 22.
    Ben-David B, Friedman M (1999) Gabapentin therapy for vulvodynia. Anesth Analg 89(6):1459–1460PubMedGoogle Scholar
  23. 23.
    Sasaki K, Smith CP, Chuang YC et al (2001) Oral Gabapentin (neurontin) treatment of refractory genitourinary tract pain. Tech Urol 7(1):47–49PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University Hospitals, Maternity HospitalAin Shams UniversityCairoEgypt

Personalised recommendations